ACP 01

Drug Profile

ACP 01

Alternative Names: ACP-01; Angiogenic Cell Precursors - Hemostemix; Endothelial progenitor cells - Hemostemix; VesCell

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TheraVitae
  • Developer Hemostemix; Mahidol University; TheraVitae
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Peripheral arterial disorders; Thromboangiitis obliterans
  • No development reported Angina pectoris; Cardiomyopathies; Heart failure

Most Recent Events

  • 23 Feb 2018 Hemostemix and Aspire Health Science agree to promote ACP 01 in Bahamas, Costa Rica, the Dominican Republic, Mexico, Panama and USA for Peripheral arterial disorders, Critical limb ischaemia, Heart failure and Coronary artery disease
  • 20 Dec 2017 Hemostemix plans a clinical trial for peripheral arterial disorders, including critical limb ischaemia in Canada and USA
  • 09 Jun 2017 ACP 01 re-licensed to Hemostemix Asia in Taiwan, China and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top